Hence, these two mechanisms, either independently and/or in combination, are likely the basis or contributing to the stronger costimulatory potential of rhCD137L-MSNs in the presence of CD137-expressing tumor cells. The gene discussed is TNFRSF9; the disease is neoplasm.